Aimovig (erenumab-aooe) is a prescription medication used for the preventive treatment of migraines in adults. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors. Aimovig is administered by subcutaneous injection and is available in two doses: 70 mg and 140 mg. Aimovig works by blocking the activity of CGRP, a molecule involved in the development of migraines. By reducing the activity of CGRP, Aimovig can help to prevent migraines from occurring or reduce their frequency.
However, as a healthcare provider, obtaining access to Aimovig enrollment forms can be time-consuming and confusing. In this article, we will provide you with access to Aimovig enrollment forms and introduce you to the AimAllyTM Support Program– which provides a variety of HCP and patient resources to streamline the process of prescribing Aimovig to treat patients.